Study of KOS-862 (Epothilone D) in Metastatic Prostate Cancer

• Status: Terminated
• Trial end date: 2005-02-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Desoxyepothilone B

Criteria

Inclusion Criteria:

• At least 18 years of age.

• Metastatic disease.

• One previous treatment including docetaxel (Taxotere).

• At least 3 weeks since last surgery/radiation/chemotherapy

• ECOG Performance Status of 0, 1 or 2

Exclusion Criteria:

• Active brain metastases